Agios Pharmaceuticals, Inc. (AGIO) vs Urogen Pharma (URGN)

Agios Pharmaceuticals, Inc. and Urogen Pharma are both Biotechnology companies. Agios Pharmaceuticals, Inc. and Urogen Pharma are of similar size ($2.0B and $2.0B). Agios Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 140.6% against 100.3%. Urogen Pharma has the higher net margin (−51.7% vs −418.2%) and the higher return on invested capital (0.00% vs −70.2%). Across the 17 metrics below, Urogen Pharma leads on 13 and Agios Pharmaceuticals, Inc. on 4.

Valuation

Metric AGIO URGN Biotechnology median
P/E n/m n/m 7.88
P/S 19.71 11.04 11.47
P/B 1.89 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 14.05 11.47 10.73
Earnings yield (21.52%) (4.79%) (28.84%)
Free cash flow yield (18.85%) (7.64%) (23.03%)

Profitability

Metric AGIO URGN Biotechnology median
Gross margin 91.99% 90.85% 65.16%
Operating margin (466.78%) (35.32%) 0.00%
Net margin (418.24%) (51.73%) 0.00%
Free cash flow margin (371.43%) (84.32%) 0.00%
Return on equity (34.34%) 86.49% (57.72%)
Return on assets (31.89%) (42.33%) (49.22%)
Return on invested capital (70.24%) 0.00% 0.00%

Growth

Metric AGIO URGN Biotechnology median
Revenue growth (TTM) 140.58% 100.27% 5.64%
EPS growth (last fiscal year) (161.17%) (7.77%) —
Revenue growth, 5-year CAGR (14.45%) 56.22% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AGIO URGN Biotechnology median
Debt to equity 0.00 (1.45) 0.00
Current ratio 10.22 3.80 4.73
Net debt to EBITDA 1.80 0.00 0.96

Dividend

Metric AGIO URGN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric AGIO URGN Biotechnology median
Market cap 2.00b 2.02b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack